Grant: Idea to Innovation
University of Toronto
$14,775.00
An Assessment of Market Opportunities for ReFilx: A Novel Soft Tissue Filler
EF 2016-17
Résumé
Lumpectomy or breast conserving surgery (BCS) is an essential component of most breast cancer (BC) treatments but it can often result in poor cosmetic outcomes due to large soft tissue defects from the procedure. There is an increasing demand for better cosmetic outcomes as these patients are now expected to survive long-term, and poor cosmesis can often serve as a constant reminder of their illness, which in turn may impact their quality of life. ReFilx, which is the invention discussed in this grant proposal, represents a simple, cost-effective, versatile, permanent and aesthetically superior solution for soft tissue defect correction with the potential of reducing surgery time/surgical dissection, complication rates and the incidence of positive margins. ReFilx is a sub-group of novel amino acid-derived biodegradable polyurethane (PU) porous foams that are intended for use as soft tissue fillers for breast volume restoration following BCS or biopsies associated with BC. Our in vivo porcine studies have shown that ReFilx satisfies the implant criteria of preserving breast shape/volume and natural stiffness, supporting cell/tissue infiltration, neovascularization and host tissue integration as well as promoting wound repair and low inflammation simultaneously. The main aim of the proposed market assessment is to assess the market potential of the proposed product through assessment of market size, competitive landscape, barriers to entry, and market trends. Analysis will also be performed to assess potential factors affecting the commercialization of the technology, including issues regarding product adoption by end-users, product positioning, potential distribution channels, regulatory factors, and reimbursement through insurance.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
501975-2016
Name nom
Santerre, Paul
Department département
Dentistry, Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
14775
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
An Assessment of Market Opportunities for ReFilx: A Novel Soft Tissue Filler
Keyword
NSERC
Application summary
Lumpectomy or breast conserving surgery (BCS) is an essential component of most breast cancer (BC) treatments but it can often result in poor cosmetic outcomes due to large soft tissue defects from the procedure. There is an increasing demand for better cosmetic outcomes as these patients are now expected to survive long-term, and poor cosmesis can often serve as a constant reminder of their illness, which in turn may impact their quality of life. ReFilx, which is the invention discussed in this grant proposal, represents a simple, cost-effective, versatile, permanent and aesthetically superior solution for soft tissue defect correction with the potential of reducing surgery time/surgical dissection, complication rates and the incidence of positive margins. ReFilx is a sub-group of novel amino acid-derived biodegradable polyurethane (PU) porous foams that are intended for use as soft tissue fillers for breast volume restoration following BCS or biopsies associated with BC. Our in vivo porcine studies have shown that ReFilx satisfies the implant criteria of preserving breast shape/volume and natural stiffness, supporting cell/tissue infiltration, neovascularization and host tissue integration as well as promoting wound repair and low inflammation simultaneously. The main aim of the proposed market assessment is to assess the market potential of the proposed product through assessment of market size, competitive landscape, barriers to entry, and market trends. Analysis will also be performed to assess potential factors affecting the commercialization of the technology, including issues regarding product adoption by end-users, product positioning, potential distribution channels, regulatory factors, and reimbursement through insurance.